Evoke Pharma (NASDAQ:EVOK) Research Coverage Started at StockNews.com

StockNews.com started coverage on shares of Evoke Pharma (NASDAQ:EVOKGet Rating) in a research report issued on Wednesday. The brokerage set a “sell” rating on the specialty pharmaceutical company’s stock.

Shares of EVOK stock opened at $0.86 on Wednesday. The business’s fifty day moving average price is $0.51 and its 200 day moving average price is $0.70. Evoke Pharma has a 1-year low of $0.36 and a 1-year high of $1.81. The firm has a market capitalization of $28.31 million, a PE ratio of -3.31 and a beta of 0.77. The company has a debt-to-equity ratio of 1.41, a current ratio of 7.51 and a quick ratio of 7.38.

Evoke Pharma (NASDAQ:EVOKGet Rating) last announced its quarterly earnings data on Tuesday, March 8th. The specialty pharmaceutical company reported ($0.05) earnings per share for the quarter. Evoke Pharma had a negative return on equity of 154.99% and a negative net margin of 529.48%. The business had revenue of $0.36 million for the quarter.

A number of hedge funds have recently made changes to their positions in EVOK. Marshall Wace LLP acquired a new position in Evoke Pharma during the first quarter worth $139,000. Renaissance Technologies LLC acquired a new position in Evoke Pharma during the fourth quarter worth $25,000. Geode Capital Management LLC grew its holdings in Evoke Pharma by 19.7% during the third quarter. Geode Capital Management LLC now owns 234,309 shares of the specialty pharmaceutical company’s stock worth $304,000 after acquiring an additional 38,549 shares during the period. Virtu Financial LLC grew its holdings in Evoke Pharma by 192.5% in the fourth quarter. Virtu Financial LLC now owns 55,336 shares of the specialty pharmaceutical company’s stock valued at $31,000 after purchasing an additional 36,418 shares during the last quarter. Finally, BlackRock Inc. grew its holdings in Evoke Pharma by 9.2% in the third quarter. BlackRock Inc. now owns 175,559 shares of the specialty pharmaceutical company’s stock valued at $228,000 after purchasing an additional 14,789 shares during the last quarter. 12.88% of the stock is currently owned by hedge funds and other institutional investors.

About Evoke Pharma (Get Rating)

Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It is developing Gimoti, a metoclopramide nasal spray that has completed Phase 3 clinical trials to treat symptoms associated with acute and recurrent diabetic gastroparesis in females.

Featured Articles

Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.